Personalis Inc (STU:04X)
€ 1.231 -0.088 (-6.67%) Market Cap: 64.37 Mil Enterprise Value: 19.49 Mil PE Ratio: 0 PB Ratio: 0.57 GF Score: 65/100

Personalis Inc Clinical Update Call Transcript

Oct 24, 2023 / 01:00PM GMT
Release Date Price: €1.02 (+14.46%)
Operator

Greetings, and welcome to Personalis Clinical Update Call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Rich Chen, Chief Medical Officer and EVP of R&D. Thank you, Mr. Chen.

Richard Chen
Personalis, Inc. - Executive VP of R&D and Chief Medical Officer

Good morning, everyone, and welcome to our webinar today. I'm Richard Chen, Chief Medical Officer and EVP of R&D of Personalis. Also here is our CEO, Chris Hall; and our CFO, Aaron Tachibana. We are absolutely thrilled to be joined today by Dr. Charlie Swanton, Cancer Research UK's Chief Clinician and Professor at the Francis Crick Institute, world renowned for his pioneering work in cancer genomics and cancer evolution.

Dr. Swanton has graciously agreed to walk us through new exciting results from their groundbreaking TRACERx lung cancer study where they use our next personal test for cancer detection. And this data was just presented a few days ago at the ESMO Conference in Madrid. So before turning it over to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot